Swedish Orphan Biovitrum’s Pivotal Phase 3 Study Did Not Meet Primary Endpoint

March 26, 2014 Swedish Orphan Biovitrum AB (publ) (Sobi) today announced topline data from the company’s pivotal phase 3 study of its enzyme therapy Kiobrina (rhBSSL – recombinant human Bile Salt Stimulated Lipase). The primary endpoint of the study – growth velocity measured after four weeks of treatment with rhBSSL – was not met. No statistically significant improvement in growth …